Silo Pharma and Medspray Enter into Agreement For PTSD Treatment

Silo Pharma, Inc., a developmental stage biopharmaceutical company focused on combining traditional therapeutics with psychedelic research, announced a new exclusive license agreement with medical technology manufacturer Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, which was chosen as the delivery mechanism for Silo's intranasal therapeutic drug SPC-15.

“We began a collaboration with Medspray earlier this year for feasibility studies evaluating its patented technology as a delivery mechanism for our intranasal therapeutic drug SPC-15. Based on successful outcomes from these studies, we have selected Medspray’s Spray Technology for our formulation,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “As part of our manufacturing and sales contract, we have obtained exclusive rights to its spray mist technology for use with multiple indications including post-traumatic stress disorder (PTSD) and anxiety, as well as Alzheimer’s disease and anorexia. We believe these rights are a valuable asset that can support Silo’s continuing research and development of novel therapeutics.”

Medspray develops and manufactures a soft mist nasal spray technology using silicon microchip-based spray nozzles. A formulation-specific, customized aerosol plume that is designed to allow for better deposition in the relevant region of the nasal cavity, thereby reducing levels of systemic absorption, as per Silo Pharma. 

The medication distribution from the nose to the brain has been optimized for patient safety and therapeutic administration.

SPC-15 is a new 5-HT4 receptor agonist that uses biomarkers to treat PTSD, anxiety, and other stress-related affective disorders. SPC-15 is being researched for use as an intranasal medicine. SPC-15 may be eligible for the FDA's simplified 505(b)(2) regulatory process for medication registration if clinical trials are successful. Silo Pharma is collaborating with Columbia University on preclinical investigations of SPC-15 under a funded research agreement and option.